Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cardiomind.com

Founded Year

2003

Stage

Acquired | Acquired

Total Raised

$48.1M

Valuation

$0000 

About CardioMind

Cardiomind is developing innovative small diameter delivery devices and stents potentially useful in treating a variety of neurological and cardiovascular disease conditions.

CardioMind Headquarters Location

257 Humboldt Court

Sunnyvale, California, 94089,

United States

408-329-5200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CardioMind Patents

CardioMind has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/22/2006

4/20/2010

Implants (medicine), Prosthetics, Vascular diseases, Interventional cardiology, Cardiology

Grant

Application Date

3/22/2006

Grant Date

4/20/2010

Title

Related Topics

Implants (medicine), Prosthetics, Vascular diseases, Interventional cardiology, Cardiology

Status

Grant

  • When was CardioMind founded?

    CardioMind was founded in 2003.

  • Where is CardioMind's headquarters?

    CardioMind's headquarters is located at 257 Humboldt Court, Sunnyvale.

  • What is CardioMind's latest funding round?

    CardioMind's latest funding round is Acquired.

  • How much did CardioMind raise?

    CardioMind raised a total of $48.1M.

  • Who are the investors of CardioMind?

    Investors of CardioMind include Biosensors International, InterWest Partners, Morgenthaler Ventures, ONSET Ventures, Latterell Venture Partners and 4 more.

  • Who are CardioMind's competitors?

    Competitors of CardioMind include Endologix, Tryton Medical, Veryan Medical, Flexible Stenting Solutions, TriReme Medical and 12 more.

You May Also Like

R
Reva Medical

REVA Medical develops interventional medical devices that leverage the company's stent designs and biomaterials to improve the treatment of vascular disease. Its flagship product is called MOTIV, a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product is utilized for the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The company was founded in 1998 and is based in San Diego, California.

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

A
Afferent

Afferent Corporation, based in Providence, Rhode Island, is developing of a new class of medical devices to treat chronic neurologic dysfunction. Its lead technology enhances the function of mechanoreceptor cells involved in sensory perception as a means to restore brain function following a stroke, to address complications resulting from diabetic neuropathy, and to improve elderly balance. Afferent's development efforts are being pursued in collaboration with leading biomedical and clinical researchers throughout the United States. Building on this technology platform, Afferent aims to establish a leadership position in the emerging field of neurotherapeutic devices.

O
OmniSonics Medical Technologies

OmniSonics was a medical device company focused on developing breakthrough products for the treatment of vascular occlusive disease.

T
TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

I
Intersect Partners

Intersect Partners is a California based medical devices company. The company primarily produces intragastric balloons, stent-like neurological medical devices, and associated minimally invasive drug delivery and device systems.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.